TY - JOUR
T1 - Tissue penetration of meropenem in patients undergoing gynecologic surgery
AU - Gall, Stanley
AU - Hemsell, David L.
AU - McGregor, James A.
AU - Martens, Mark G.
AU - Pitkin, Donald
AU - Allen, Sarah
PY - 1997
Y1 - 1997
N2 - The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.
AB - The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.
UR - http://www.scopus.com/inward/record.url?scp=0030891496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030891496&partnerID=8YFLogxK
U2 - 10.1093/clinids/24.supplement_2.s178
DO - 10.1093/clinids/24.supplement_2.s178
M3 - Article
C2 - 9126690
AN - SCOPUS:0030891496
SN - 1058-4838
VL - 24
SP - S178-S180
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 2
ER -